Evidence map›Paper›PMID 41918532›Full record

ArticleFrontiers in microbiology2026

Timing-specific efficacy of antiviral baloxavir and anti-inflammatory oclacitinib monotherapies, and the benefits of their combination in treating influenza in mice.

Yang Yu, Lefang Jiang, Jiaxin Ke, Xiaoqin Lian, Yarou Gao, Xingjian Zhu, Mingxin Zhang, Huixia Wu, Xulin Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yang Yu *Department of Immunology and Microbiology, College of Life Science and Technology, Institute of Medical Microbiology, Jinan University, Guangzhou, China.
Lefang Jiang *Department of Immunology and Microbiology, College of Life Science and Technology, Institute of Medical Microbiology, Jinan University, Guangzhou, China.
Jiaxin KeDepartment of Immunology and Microbiology, College of Life Science and Technology, Institute of Medical Microbiology, Jinan University, Guangzhou, China.
Xiaoqin LianDepartment of Immunology and Microbiology, College of Life Science and Technology, Institute of Medical Microbiology, Jinan University, Guangzhou, China.
Yarou GaoDepartment of Immunology and Microbiology, College of Life Science and Technology, Institute of Medical Microbiology, Jinan University, Guangzhou, China.
Xingjian ZhuDepartment of Immunology and Microbiology, College of Life Science and Technology, Institute of Medical Microbiology, Jinan University, Guangzhou, China.
Mingxin ZhangDepartment of Immunology and Microbiology, College of Life Science and Technology, Institute of Medical Microbiology, Jinan University, Guangzhou, China.
Huixia WuDepartment of Rheumatology, First Affiliated Hospital, Jinan University, Guangzhou, China.
Xulin ChenDepartment of Immunology and Microbiology, College of Life Science and Technology, Institute of Medical Microbiology, Jinan University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Excessive inflammation from uncontrolled pro-inflammatory cytokine release is a leading cause of mortality in influenza virus infections. Anti-inflammatory therapies, particularly Janus kinase (JAK) inhibitors, have demonstrated protective effects in murine models against lethal influenza virus infections, particularly during the later stages of infection. This study investigates the potential synergy of combining antiviral and anti-inflammatory medications to extend the treatment window for influenza. We assessed the

Indexed as

anti-inflammatoryantiviralbaloxavircombination therapyinfluenza virusJanus kinase (JAK) inhibitorsoclacitinib

Identifiers

PMID41918532
PMCPMC13033785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.